Locally advanced esophageal adenocarcinoma or squamous cell carcinoma
Conditions
Interventions
Patients receive treatment according to standard clinical care during the conduct of the study. Patients who participate in this study will undergo one FDG-PET/MRI scan in total, planned sequentially
Sponsors
Erasmus MC
Eligibility
Inclusion criteria
Inclusion criteria: - Age =18 years; - Histologically proven esophageal adenocarcinoma or squamous cell carcinoma located caudally to the carina; - Completed neoadjuvant chemoradiotherapy (nCRT); - Scheduled to undergo FDG-PET/CT at 4-6 weeks after nCRT or at 8-12 weeks after nCRT.
Exclusion criteria
Exclusion criteria: - Contra-indications for MRI (e.g. pacemaker, metal implant, claustrophobia); - Contra-indications for iodinated contrast media (e.g. previous contrast-allergy or eGFR <30 ml/min/1,73m2); - FDG-non avid tumor as determined from the pre-treatment PET/CT scan; - Incapacitated patients, prohibiting the understanding and giving of informed consent and to complete the questionnaire on experienced burden with PET/MRI.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary study parameter is qualitative re-staging after nCRT based on FDG-PET/MRI versus FDG-PET/CT, with pathology as gold standard (i.e. histopathologic assessment of the resection specimen when patients undergo surgery after nCRT, or histopathology/cytopathology of the primary tumor and suspected (distant) metastases as obtained during standard follow-up when patients do not undergo surgery or postpone surgery after nCRT). | — |
Secondary
| Measure | Time frame |
|---|---|
| Experienced burden of undergoing FDG-PET/MRI; quantitative measurements of the primary tumor and lymph nodes. | — |
Contacts
Public ContactMaartje Valkema
Erasmus MC
Outcome results
None listed